Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2009
|
| gptkbp:ATCCode |
L01XE11
|
| gptkbp:bioavailability |
~21% (oral)
|
| gptkbp:CASNumber |
444731-52-6
|
| gptkbp:chemicalFormula |
C21H23N7O2S
|
| gptkbp:drugClass |
antineoplastic agent
|
| gptkbp:eliminationHalfLife |
~30 hours
|
| gptkbp:genericName |
gptkb:pazopanib
|
| https://www.w3.org/2000/01/rdf-schema#label |
Votrient
|
| gptkbp:indication |
gptkb:rhabdomyosarcoma
renal cell carcinoma |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
GlaxoSmithKline
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:metabolism |
liver (CYP3A4)
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:proteinBinding |
>99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue hypertension hair color changes |
| gptkbp:target |
gptkb:PDGFR
gptkb:VEGFR gptkb:c-Kit |
| gptkbp:bfsParent |
gptkb:NOVN
|
| gptkbp:bfsLayer |
5
|